

# Local Coverage Determination (LCD): RAST Type Tests (L33591)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

---

## Contractor Information

Contractor Name	Contract Type	Contract Number	Jurisdiction	State(s)
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06101 - MAC A	N/A	Illinois
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06102 - MAC B	N/A	Illinois
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06201 - MAC A	N/A	Minnesota
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06202 - MAC B	N/A	Minnesota
<a href="#">National Government Services, Inc.</a>	MAC - Part A	06301 - MAC A	N/A	Wisconsin
<a href="#">National Government Services, Inc.</a>	MAC - Part B	06302 - MAC B	N/A	Wisconsin
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13101 - MAC A	J - K	Connecticut
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13102 - MAC B	J - K	Connecticut
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13201 - MAC A	J - K	New York - Entire State
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13202 - MAC B	J - K	New York - Downstate
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13282 - MAC B	J - K	New York - Upstate
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	13292 - MAC B	J - K	New York - Queens
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14111 - MAC A	J - K	Maine
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14112 - MAC B	J - K	Maine
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14211 - MAC A	J - K	Massachusetts
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14212 - MAC B	J - K	Massachusetts
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14311 - MAC A	J - K	New Hampshire
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14312 - MAC B	J - K	New Hampshire
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14411 - MAC A	J - K	Rhode Island
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14412 - MAC B	J - K	Rhode Island
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14511 - MAC A	J - K	Vermont
<a href="#">National Government Services, Inc.</a>	A and B and HHH MAC	14512 - MAC B	J - K	Vermont

[Back to Top](#)

---

## LCD Information

### Document Information

LCD ID

Original Effective Date

L33591

For services performed on or after 10/01/2015

Original ICD-9 LCD ID  
[L28463](#)

Revision Effective Date  
For services performed on or after 10/01/2015

LCD Title  
RAST Type Tests

Revision Ending Date  
N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement  
CPT only copyright 2002-2016 American Medical Association. All Rights Reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Retirement Date  
N/A

Notice Period Start Date  
N/A

Notice Period End Date  
N/A

The Code on Dental Procedures and Nomenclature (Code) is published in Current Dental Terminology (CDT). Copyright © American Dental Association. All rights reserved. CDT and CDT-2016 are trademarks of the American Dental Association.

UB-04 Manual. OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2014, is copyrighted by American Hospital Association (“AHA”), Chicago, Illinois. No portion of OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA.” Health Forum reserves the right to change the copyright notice from time to time upon written notice to Company.

CMS National Coverage Policy Language quoted from Centers for Medicare and Medicaid Services (CMS), National Coverage Determinations (NCDs) and coverage provisions in interpretive manuals is italicized throughout the policy. NCDs and coverage provisions in interpretive manuals are not subject to the Local Coverage Determination (LCD) Review Process (42 CFR 405.860[b] and 42 CFR 426 [Subpart D]). In addition, an administrative law judge may not review an NCD. See Section 1869(f)(1)(A)(i) of the Social Security Act.

Unless otherwise specified, italicized text represents quotation from one or more of the following CMS sources:

Title XVIII of the Social Security Act (SSA):

Section 1862 (a)(1)(A) allows coverage and payment for only those services considered medically reasonable and necessary.

Section 1833 (e) prohibits Medicare payment for any claim which lacks the necessary information to process the claim.

Coverage Guidance  
Coverage Indications, Limitations, and/ or Medical Necessity

Abstract:

Radioallergosorbent test (RAST), fluoroallergosorbent test (FAST), and multiple antigen simultaneous tests are in vitro techniques for determining whether a patient's serum contains IgE antibodies against specific allergens of clinical importance. As with any allergy testing, the need for such tests is based on the findings during a complete

history and physical examination of the patient.

The multiple antigen simultaneous testing technique is similar to the RAST/FAST techniques in that it depends upon the existence of allergic antibodies in the blood of the patient being tested. With the multiple antigen simultaneous test system, several antigens may be used to test for specific IgE simultaneously.

ELISA (enzyme-linked immunosorbent assay) is another in vitro method of allergy testing for specific IgE antibodies against allergens. This method is also a variation of RAST.

Limitations:

The following tests are considered to be not medically necessary and will be denied.

- ELISA/Act qualitative antibody testing  
This testing is used to determine in vitro reaction to various foods and relies on lymphocyte blastogenesis in response to certain food antigens.
- LMRA (Lymphocyte Mitogen Response Assays) by ELISA/Act
- IgG ELISA, indirect method (CPT code 86001)
- Qualitative multi-allergen screen (CPT code 86005)  
This is a non-specific test that does not identify a specific antigen.
- IgG and IgG subclass antibody tests for food allergy do not have clinical relevance, are not validated, lack sufficient quality control, and should not be performed.

[Back to Top](#)

---

## Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

011x Hospital Inpatient (Including Medicare Part A)  
012x Hospital Inpatient (Medicare Part B only)  
013x Hospital Outpatient  
014x Hospital - Laboratory Services Provided to Non-patients  
071x Clinic - Rural Health  
073x Clinic - Freestanding  
077x Clinic - Federally Qualified Health Center (FQHC)  
085x Critical Access Hospital

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

Revenue codes only apply to providers who bill these services to the Part A MAC. Revenue codes do not apply to physicians, other professionals and suppliers who bill these services to the Part B MAC.

Please note that not all revenue codes apply to every type of bill code. Providers are encouraged to refer to the FISS revenue code file for allowable bill types. Similarly, not all revenue codes apply to each CPT/HCPCS code. Providers are encouraged to refer to the FISS HCPCS file for allowable revenue codes.

All revenue codes billed on the inpatient claim for the dates of service in question may be subject to review.

0300 Laboratory - General Classification

0302 Laboratory - Immunology

0309 Laboratory - Other Laboratory

0971 Professional Fees - Laboratory

#### CPT/HCPCS Codes

Group 1 Paragraph: CPT codes 86001 and 86005 are not covered services.

#### Group 1 Codes:

86001 ALLERGEN SPECIFIC IGG QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN

86003 ALLERGEN SPECIFIC IGE; QUANTITATIVE OR SEMIQUANTITATIVE, EACH ALLERGEN

86005 ALLERGEN SPECIFIC IGE; QUALITATIVE, MULTIALLERGEN SCREEN (DIPSTICK, PADDLE, OR DISK)

#### ICD-10 Codes that Support Medical Necessity

Group 1 Paragraph: The use of an ICD-10-CM code listed below does not assure coverage of a service. The service must be reasonable and necessary in the specific case and must meet the criteria specified in this determination.

The following ICD-10 Codes apply only to CPT code 86003:

#### Group 1 Codes:

ICD-10 Codes	Description
J30.0	Vasomotor rhinitis
J30.1	Allergic rhinitis due to pollen
J30.2	Other seasonal allergic rhinitis
J30.5	Allergic rhinitis due to food
J30.81	Allergic rhinitis due to animal (cat) (dog) hair and dander
J30.89	Other allergic rhinitis
J30.9	Allergic rhinitis, unspecified
J45.20	Mild intermittent asthma, uncomplicated
J45.21	Mild intermittent asthma with (acute) exacerbation
J45.22	Mild intermittent asthma with status asthmaticus
J45.30	Mild persistent asthma, uncomplicated
J45.31	Mild persistent asthma with (acute) exacerbation
J45.32	Mild persistent asthma with status asthmaticus
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus
J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma
L20.0	Besnier's prurigo
L20.81	Atopic neurodermatitis
L20.82	Flexural eczema
L20.84	Intrinsic (allergic) eczema
L20.89	Other atopic dermatitis
L50.0	Allergic urticaria
L50.6	Contact urticaria
L50.8	Other urticaria

ICD-10 Codes	Description
L50.9	Urticaria, unspecified
R06.2	Wheezing
<a href="#">T36.0X5A</a> - <a href="#">T36.0X5S</a>	Adverse effect of penicillins, initial encounter - Adverse effect of penicillins, sequela
<a href="#">T36.1X5A</a> - <a href="#">T36.1X5S</a>	Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter - Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela
<a href="#">T36.2X5A</a> - <a href="#">T36.2X5S</a>	Adverse effect of chloramphenicol group, initial encounter - Adverse effect of chloramphenicol group, sequela
<a href="#">T36.3X5A</a> - <a href="#">T36.3X5S</a>	Adverse effect of macrolides, initial encounter - Adverse effect of macrolides, sequela
<a href="#">T36.4X5A</a> - <a href="#">T36.4X5S</a>	Adverse effect of tetracyclines, initial encounter - Adverse effect of tetracyclines, sequela
<a href="#">T36.5X5A</a> - <a href="#">T36.5X5S</a>	Adverse effect of aminoglycosides, initial encounter - Adverse effect of aminoglycosides, sequela
<a href="#">T36.6X5A</a> - <a href="#">T36.6X5S</a>	Adverse effect of rifampicins, initial encounter - Adverse effect of rifampicins, sequela
<a href="#">T36.7X5A</a> - <a href="#">T36.7X5S</a>	Adverse effect of antifungal antibiotics, systemically used, initial encounter - Adverse effect of antifungal antibiotics, systemically used, sequela
<a href="#">T36.8X5A</a> - <a href="#">T36.8X5S</a>	Adverse effect of other systemic antibiotics, initial encounter - Adverse effect of other systemic antibiotics, sequela
<a href="#">T36.95XA</a> - <a href="#">T36.95XS</a>	Adverse effect of unspecified systemic antibiotic, initial encounter - Adverse effect of unspecified systemic antibiotic, sequela
<a href="#">T37.0X5A</a> - <a href="#">T37.0X5S</a>	Adverse effect of sulfonamides, initial encounter - Adverse effect of sulfonamides, sequela
<a href="#">T37.1X5A</a> - <a href="#">T37.1X5S</a>	Adverse effect of antimycobacterial drugs, initial encounter - Adverse effect of antimycobacterial drugs, sequela
<a href="#">T37.2X5A</a> - <a href="#">T37.2X5S</a>	Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter - Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela
<a href="#">T37.3X5A</a> - <a href="#">T37.3X5S</a>	Adverse effect of other antiprotozoal drugs, initial encounter - Adverse effect of other antiprotozoal drugs, sequela
<a href="#">T37.4X5A</a> - <a href="#">T37.4X5S</a>	Adverse effect of anthelmintics, initial encounter - Adverse effect of anthelmintics, sequela
<a href="#">T37.5X5A</a> - <a href="#">T37.5X5S</a>	Adverse effect of antiviral drugs, initial encounter - Adverse effect of antiviral drugs, sequela
<a href="#">T37.8X5A</a> - <a href="#">T37.8X5S</a>	Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter - Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela
<a href="#">T37.95XA</a> - <a href="#">T37.95XS</a>	Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter - Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela
<a href="#">T38.0X5A</a> - <a href="#">T38.0X5S</a>	Adverse effect of glucocorticoids and synthetic analogues, initial encounter - Adverse effect of glucocorticoids and synthetic analogues, sequela
<a href="#">T38.1X5A</a> - <a href="#">T38.1X5S</a>	Adverse effect of thyroid hormones and substitutes, initial encounter - Adverse effect of thyroid hormones and substitutes, sequela
<a href="#">T38.2X5A</a> - <a href="#">T38.2X5S</a>	Adverse effect of antithyroid drugs, initial encounter - Adverse effect of antithyroid drugs, sequela
<a href="#">T38.4X5A</a> - <a href="#">T38.4X5S</a>	Adverse effect of oral contraceptives, initial encounter - Adverse effect of oral contraceptives, sequela
<a href="#">T38.5X5A</a> - <a href="#">T38.5X5S</a>	Adverse effect of other estrogens and progestogens, initial encounter - Adverse effect of other estrogens and progestogens, sequela
<a href="#">T38.6X5A</a> - <a href="#">T38.6X5S</a>	Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter - Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela
<a href="#">T38.7X5A</a> - <a href="#">T38.7X5S</a>	Adverse effect of androgens and anabolic congeners, initial encounter - Adverse effect of androgens and anabolic congeners, sequela
<a href="#">T38.805A</a> - <a href="#">T38.805S</a>	Adverse effect of unspecified hormones and synthetic substitutes, initial encounter - Adverse effect of unspecified hormones and synthetic substitutes, sequela
<a href="#">T38.815A</a> - <a href="#">T38.815S</a>	Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter - Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela
<a href="#">T38.895A</a> - <a href="#">T38.895S</a>	Adverse effect of other hormones and synthetic substitutes, initial encounter - Adverse effect of other hormones and synthetic substitutes, sequela
<a href="#">T38.905A</a> - <a href="#">T38.905S</a>	Adverse effect of unspecified hormone antagonists, initial encounter - Adverse effect of unspecified hormone antagonists, sequela

ICD-10 Codes	Description
<a href="#">T38.995A - T38.995S</a>	Adverse effect of other hormone antagonists, initial encounter - Adverse effect of other hormone antagonists, sequela
<a href="#">T39.015A - T39.015S</a>	Adverse effect of aspirin, initial encounter - Adverse effect of aspirin, sequela
<a href="#">T39.095A - T39.095S</a>	Adverse effect of salicylates, initial encounter - Adverse effect of salicylates, sequela
<a href="#">T39.1X5A - T39.1X5S</a>	Adverse effect of 4-Aminophenol derivatives, initial encounter - Adverse effect of 4-Aminophenol derivatives, sequela
<a href="#">T39.2X5A - T39.2X5S</a>	Adverse effect of pyrazolone derivatives, initial encounter - Adverse effect of pyrazolone derivatives, sequela
<a href="#">T39.315A - T39.315S</a>	Adverse effect of propionic acid derivatives, initial encounter - Adverse effect of propionic acid derivatives, sequela
<a href="#">T39.395A - T39.395S</a>	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter - Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela
<a href="#">T39.4X5A - T39.4X5S</a>	Adverse effect of antirheumatics, not elsewhere classified, initial encounter - Adverse effect of antirheumatics, not elsewhere classified, sequela
<a href="#">T39.8X5A - T39.8X5S</a>	Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter - Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela
<a href="#">T39.95XA - T39.95XS</a>	Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter - Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela
<a href="#">T40.0X5A - T40.0X5S</a>	Adverse effect of opium, initial encounter - Adverse effect of opium, sequela
<a href="#">T40.2X5A - T40.2X5S</a>	Adverse effect of other opioids, initial encounter - Adverse effect of other opioids, sequela
<a href="#">T40.3X5A - T40.3X5S</a>	Adverse effect of methadone, initial encounter - Adverse effect of methadone, sequela
<a href="#">T40.4X5A - T40.4X5S</a>	Adverse effect of other synthetic narcotics, initial encounter - Adverse effect of other synthetic narcotics, sequela
<a href="#">T40.5X5A - T40.5X5S</a>	Adverse effect of cocaine, initial encounter - Adverse effect of cocaine, sequela
<a href="#">T40.605A - T40.605S</a>	Adverse effect of unspecified narcotics, initial encounter - Adverse effect of unspecified narcotics, sequela
<a href="#">T40.695A - T40.695S</a>	Adverse effect of other narcotics, initial encounter - Adverse effect of other narcotics, sequela
<a href="#">T40.7X5A - T40.7X5S</a>	Adverse effect of cannabis (derivatives), initial encounter - Adverse effect of cannabis (derivatives), sequela
<a href="#">T40.905A - T40.905S</a>	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter - Adverse effect of unspecified psychodysleptics [hallucinogens], sequela
<a href="#">T40.995A - T40.995S</a>	Adverse effect of other psychodysleptics [hallucinogens], initial encounter - Adverse effect of other psychodysleptics [hallucinogens], sequela
<a href="#">T41.0X5A - T41.0X5S</a>	Adverse effect of inhaled anesthetics, initial encounter - Adverse effect of inhaled anesthetics, sequela
<a href="#">T41.1X5A - T41.1X5S</a>	Adverse effect of intravenous anesthetics, initial encounter - Adverse effect of intravenous anesthetics, sequela
<a href="#">T41.295A - T41.295S</a>	Adverse effect of other general anesthetics, initial encounter - Adverse effect of other general anesthetics, sequela
<a href="#">T41.3X5A - T41.3X5S</a>	Adverse effect of local anesthetics, initial encounter - Adverse effect of local anesthetics, sequela
<a href="#">T41.5X5A - T41.5X5S</a>	Adverse effect of therapeutic gases, initial encounter - Adverse effect of therapeutic gases, sequela
<a href="#">T42.0X5A - T42.0X5S</a>	Adverse effect of hydantoin derivatives, initial encounter - Adverse effect of hydantoin derivatives, sequela
<a href="#">T42.1X5A - T42.1X5S</a>	Adverse effect of iminostilbenes, initial encounter - Adverse effect of iminostilbenes, sequela
<a href="#">T42.2X5A - T42.2X5S</a>	Adverse effect of succinimides and oxazolidinediones, initial encounter - Adverse effect of succinimides and oxazolidinediones, sequela
<a href="#">T42.3X5A - T42.3X5S</a>	Adverse effect of barbiturates, initial encounter - Adverse effect of barbiturates, sequela
<a href="#">T42.4X5A - T42.4X5S</a>	Adverse effect of benzodiazepines, initial encounter - Adverse effect of benzodiazepines, sequela

ICD-10 Codes	Description
<a href="#">T42.5X5A - T42.5X5S</a>	Adverse effect of mixed antiepileptics, initial encounter - Adverse effect of mixed antiepileptics, sequela
<a href="#">T42.6X5A - T42.6X5S</a>	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter - Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela
<a href="#">T42.75XA - T42.75XS</a>	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter - Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, sequela
<a href="#">T42.8X5A - T42.8X5S</a>	Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter - Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela
<a href="#">T43.015A - T43.015S</a>	Adverse effect of tricyclic antidepressants, initial encounter - Adverse effect of tricyclic antidepressants, sequela
<a href="#">T43.025A - T43.025S</a>	Adverse effect of tetracyclic antidepressants, initial encounter - Adverse effect of tetracyclic antidepressants, sequela
<a href="#">T43.1X5A - T43.1X5S</a>	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter - Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela
<a href="#">T43.205A - T43.205S</a>	Adverse effect of unspecified antidepressants, initial encounter - Adverse effect of unspecified antidepressants, sequela
<a href="#">T43.215A - T43.215S</a>	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter - Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela
<a href="#">T43.225A - T43.225S</a>	Adverse effect of selective serotonin reuptake inhibitors, initial encounter - Adverse effect of selective serotonin reuptake inhibitors, sequela
<a href="#">T43.295A - T43.295S</a>	Adverse effect of other antidepressants, initial encounter - Adverse effect of other antidepressants, sequela
<a href="#">T43.3X5A - T43.3X5S</a>	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter - Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela
<a href="#">T43.4X5A - T43.4X5S</a>	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter - Adverse effect of butyrophenone and thiothixene neuroleptics, sequela
<a href="#">T43.505A - T43.505S</a>	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter - Adverse effect of unspecified antipsychotics and neuroleptics, sequela
<a href="#">T43.595A - T43.595S</a>	Adverse effect of other antipsychotics and neuroleptics, initial encounter - Adverse effect of other antipsychotics and neuroleptics, sequela
<a href="#">T43.605A - T43.605S</a>	Adverse effect of unspecified psychostimulants, initial encounter - Adverse effect of unspecified psychostimulants, sequela
<a href="#">T43.615A - T43.615S</a>	Adverse effect of caffeine, initial encounter - Adverse effect of caffeine, sequela
<a href="#">T43.625A - T43.625S</a>	Adverse effect of amphetamines, initial encounter - Adverse effect of amphetamines, sequela
<a href="#">T43.635A - T43.635S</a>	Adverse effect of methylphenidate, initial encounter - Adverse effect of methylphenidate, sequela
<a href="#">T43.695A - T43.695S</a>	Adverse effect of other psychostimulants, initial encounter - Adverse effect of other psychostimulants, sequela
<a href="#">T43.8X5A - T43.8X5S</a>	Adverse effect of other psychotropic drugs, initial encounter - Adverse effect of other psychotropic drugs, sequela
<a href="#">T43.95XA - T43.95XS</a>	Adverse effect of unspecified psychotropic drug, initial encounter - Adverse effect of unspecified psychotropic drug, sequela
<a href="#">T44.0X5A - T44.0X5S</a>	Adverse effect of anticholinesterase agents, initial encounter - Adverse effect of anticholinesterase agents, sequela
<a href="#">T44.1X5A - T44.1X5S</a>	Adverse effect of other parasympathomimetics [cholinergics], initial encounter - Adverse effect of other parasympathomimetics [cholinergics], sequela
<a href="#">T44.2X5A - T44.2X5S</a>	Adverse effect of ganglionic blocking drugs, initial encounter - Adverse effect of ganglionic blocking drugs, sequela
<a href="#">T44.3X5A - T44.3X5S</a>	Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter - Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela
<a href="#">T44.4X5A - T44.4X5S</a>	Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter - Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela
<a href="#">T44.5X5A - T44.5X5S</a>	Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter - Adverse effect of predominantly beta-adrenoreceptor agonists, sequela
<a href="#">T44.6X5A - T44.6X5S</a>	Adverse effect of alpha-adrenoreceptor antagonists, initial encounter - Adverse effect of alpha-adrenoreceptor antagonists, sequela

ICD-10 Codes	Description
<a href="#">T44.7X5A</a> - <a href="#">T44.7X5S</a>	Adverse effect of beta-adrenoreceptor antagonists, initial encounter - Adverse effect of beta-adrenoreceptor antagonists, sequela
<a href="#">T44.8X5A</a> - <a href="#">T44.8X5S</a>	Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter - Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela
<a href="#">T44.905A</a> - <a href="#">T44.905S</a>	Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter - Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela
<a href="#">T44.995A</a> - <a href="#">T44.995S</a>	Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter - Adverse effect of other drug primarily affecting the autonomic nervous system, sequela
<a href="#">T45.0X5A</a> - <a href="#">T45.0X5S</a>	Adverse effect of antiallergic and antiemetic drugs, initial encounter - Adverse effect of antiallergic and antiemetic drugs, sequela
<a href="#">T45.1X5A</a> - <a href="#">T45.1X5S</a>	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter - Adverse effect of antineoplastic and immunosuppressive drugs, sequela
<a href="#">T45.2X5A</a> - <a href="#">T45.2X5S</a>	Adverse effect of vitamins, initial encounter - Adverse effect of vitamins, sequela
<a href="#">T45.3X5A</a> - <a href="#">T45.3X5S</a>	Adverse effect of enzymes, initial encounter - Adverse effect of enzymes, sequela
<a href="#">T45.4X5A</a> - <a href="#">T45.4X5S</a>	Adverse effect of iron and its compounds, initial encounter - Adverse effect of iron and its compounds, sequela
<a href="#">T45.515A</a> - <a href="#">T45.515S</a>	Adverse effect of anticoagulants, initial encounter - Adverse effect of anticoagulants, sequela
<a href="#">T45.525A</a> - <a href="#">T45.525S</a>	Adverse effect of antithrombotic drugs, initial encounter - Adverse effect of antithrombotic drugs, sequela
<a href="#">T45.605A</a> - <a href="#">T45.605S</a>	Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter - Adverse effect of unspecified fibrinolysis-affecting drugs, sequela
<a href="#">T45.615A</a> - <a href="#">T45.615S</a>	Adverse effect of thrombolytic drugs, initial encounter - Adverse effect of thrombolytic drugs, sequela
<a href="#">T45.625A</a> - <a href="#">T45.625S</a>	Adverse effect of hemostatic drug, initial encounter - Adverse effect of hemostatic drug, sequela
<a href="#">T45.695A</a> - <a href="#">T45.695S</a>	Adverse effect of other fibrinolysis-affecting drugs, initial encounter - Adverse effect of other fibrinolysis-affecting drugs, sequela
<a href="#">T45.7X5A</a> - <a href="#">T45.7X5S</a>	Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter - Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela
<a href="#">T45.8X5A</a> - <a href="#">T45.8X5S</a>	Adverse effect of other primarily systemic and hematological agents, initial encounter - Adverse effect of other primarily systemic and hematological agents, sequela
<a href="#">T45.95XA</a> - <a href="#">T45.95XS</a>	Adverse effect of unspecified primarily systemic and hematological agent, initial encounter - Adverse effect of unspecified primarily systemic and hematological agent, sequela
<a href="#">T46.0X5A</a> - <a href="#">T46.0X5S</a>	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela
<a href="#">T46.1X5A</a> - <a href="#">T46.1X5S</a>	Adverse effect of calcium-channel blockers, initial encounter - Adverse effect of calcium-channel blockers, sequela
<a href="#">T46.2X5A</a> - <a href="#">T46.2X5S</a>	Adverse effect of other antidysrhythmic drugs, initial encounter - Adverse effect of other antidysrhythmic drugs, sequela
<a href="#">T46.3X5A</a> - <a href="#">T46.3X5S</a>	Adverse effect of coronary vasodilators, initial encounter - Adverse effect of coronary vasodilators, sequela
<a href="#">T46.4X5A</a> - <a href="#">T46.4X5S</a>	Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter - Adverse effect of angiotensin-converting-enzyme inhibitors, sequela
<a href="#">T46.5X5A</a> - <a href="#">T46.5X5S</a>	Adverse effect of other antihypertensive drugs, initial encounter - Adverse effect of other antihypertensive drugs, sequela
<a href="#">T46.6X5A</a> - <a href="#">T46.6X5S</a>	Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela
<a href="#">T46.7X5A</a> - <a href="#">T46.7X5S</a>	Adverse effect of peripheral vasodilators, initial encounter - Adverse effect of peripheral vasodilators, sequela
<a href="#">T46.8X5A</a> - <a href="#">T46.8X5S</a>	Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter - Adverse effect of antivaricose drugs, including sclerosing agents, sequela
<a href="#">T46.905A</a> - <a href="#">T46.905S</a>	Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter - Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela
<a href="#">T46.995A</a> - <a href="#">T46.995S</a>	Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter - Adverse effect of other agents primarily affecting the cardiovascular system, sequela
<a href="#">T47.0X5A</a> - <a href="#">T47.0X5S</a>	Adverse effect of histamine H2-receptor blockers, initial encounter - Adverse effect of histamine H2-receptor blockers, sequela



ICD-10 Codes	Description
<a href="#">T47.1X5A - T47.1X5S</a>	Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter - Adverse effect of other antacids and anti-gastric-secretion drugs, sequela
<a href="#">T47.2X5A - T47.2X5S</a>	Adverse effect of stimulant laxatives, initial encounter - Adverse effect of stimulant laxatives, sequela
<a href="#">T47.3X5A - T47.3X5S</a>	Adverse effect of saline and osmotic laxatives, initial encounter - Adverse effect of saline and osmotic laxatives, sequela
<a href="#">T47.4X5A - T47.4X5S</a>	Adverse effect of other laxatives, initial encounter - Adverse effect of other laxatives, sequela
<a href="#">T47.5X5A - T47.5X5S</a>	Adverse effect of digestants, initial encounter - Adverse effect of digestants, sequela
<a href="#">T47.6X5A - T47.6X5S</a>	Adverse effect of antidiarrheal drugs, initial encounter - Adverse effect of antidiarrheal drugs, sequela
<a href="#">T47.7X5A - T47.7X5S</a>	Adverse effect of emetics, initial encounter - Adverse effect of emetics, sequela
<a href="#">T47.8X5A - T47.8X5S</a>	Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter - Adverse effect of other agents primarily affecting gastrointestinal system, sequela
<a href="#">T47.95XA - T47.95XS</a>	Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter - Adverse effect of unspecified agents primarily affecting the gastrointestinal system, sequela
<a href="#">T48.0X5A - T48.0X5S</a>	Adverse effect of oxytocic drugs, initial encounter - Adverse effect of oxytocic drugs, sequela
<a href="#">T48.1X5A - T48.1X5S</a>	Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter - Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela
<a href="#">T48.205A - T48.205S</a>	Adverse effect of unspecified drugs acting on muscles, initial encounter - Adverse effect of unspecified drugs acting on muscles, sequela
<a href="#">T48.295A - T48.295S</a>	Adverse effect of other drugs acting on muscles, initial encounter - Adverse effect of other drugs acting on muscles, sequela
<a href="#">T48.3X5A - T48.3X5S</a>	Adverse effect of antitussives, initial encounter - Adverse effect of antitussives, sequela
<a href="#">T48.4X5A - T48.4X5S</a>	Adverse effect of expectorants, initial encounter - Adverse effect of expectorants, sequela
<a href="#">T48.5X5A - T48.5X5S</a>	Adverse effect of other anti-common-cold drugs, initial encounter - Adverse effect of other anti-common-cold drugs, sequela
<a href="#">T48.6X5A - T48.6X5S</a>	Adverse effect of antiasthmatics, initial encounter - Adverse effect of antiasthmatics, sequela
<a href="#">T48.905A - T48.905S</a>	Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter - Adverse effect of unspecified agents primarily acting on the respiratory system, sequela
<a href="#">T48.995A - T48.995S</a>	Adverse effect of other agents primarily acting on the respiratory system, initial encounter - Adverse effect of other agents primarily acting on the respiratory system, sequela
<a href="#">T49.0X5A - T49.0X5S</a>	Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter - Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela
<a href="#">T49.1X5A - T49.1X5S</a>	Adverse effect of antipruritics, initial encounter - Adverse effect of antipruritics, sequela
<a href="#">T49.2X5A - T49.2X5S</a>	Adverse effect of local astringents and local detergents, initial encounter - Adverse effect of local astringents and local detergents, sequela
<a href="#">T49.3X5A - T49.3X5S</a>	Adverse effect of emollients, demulcents and protectants, initial encounter - Adverse effect of emollients, demulcents and protectants, sequela
<a href="#">T49.4X5A - T49.4X5S</a>	Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter - Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela
<a href="#">T49.5X5A - T49.5X5S</a>	Adverse effect of ophthalmological drugs and preparations, initial encounter - Adverse effect of ophthalmological drugs and preparations, sequela
<a href="#">T49.6X5A - T49.6X5S</a>	Adverse effect of otorhinolaryngological drugs and preparations, initial encounter - Adverse effect of otorhinolaryngological drugs and preparations, sequela
<a href="#">T49.7X5A - T49.7X5S</a>	Adverse effect of dental drugs, topically applied, initial encounter - Adverse effect of dental drugs, topically applied, sequela
<a href="#">T49.8X5A - T49.8X5S</a>	Adverse effect of other topical agents, initial encounter - Adverse effect of other topical agents, sequela
<a href="#">T49.95XA - T49.95XS</a>	Adverse effect of unspecified topical agent, initial encounter - Adverse effect of unspecified topical agent, sequela

ICD-10 Codes	Description
<a href="#">T50.0X5A - T50.0X5S</a>	Adverse effect of mineralocorticoids and their antagonists, initial encounter - Adverse effect of mineralocorticoids and their antagonists, sequela
<a href="#">T50.1X5A - T50.1X5S</a>	Adverse effect of loop [high-ceiling] diuretics, initial encounter - Adverse effect of loop [high-ceiling] diuretics, sequela
<a href="#">T50.2X5A - T50.2X5S</a>	Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela
<a href="#">T50.3X5A - T50.3X5S</a>	Adverse effect of electrolytic, caloric and water-balance agents, initial encounter - Adverse effect of electrolytic, caloric and water-balance agents, sequela
<a href="#">T50.4X5A - T50.4X5S</a>	Adverse effect of drugs affecting uric acid metabolism, initial encounter - Adverse effect of drugs affecting uric acid metabolism, sequela
<a href="#">T50.5X5A - T50.5X5S</a>	Adverse effect of appetite depressants, initial encounter - Adverse effect of appetite depressants, sequela
<a href="#">T50.6X5A - T50.6X5S</a>	Adverse effect of antidotes and chelating agents, initial encounter - Adverse effect of antidotes and chelating agents, sequela
<a href="#">T50.7X5A - T50.7X5S</a>	Adverse effect of analeptics and opioid receptor antagonists, initial encounter - Adverse effect of analeptics and opioid receptor antagonists, sequela
<a href="#">T50.8X5A - T50.8X5S</a>	Adverse effect of diagnostic agents, initial encounter - Adverse effect of diagnostic agents, sequela
<a href="#">T50.A15A - T50.A15S</a>	Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter - Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela
<a href="#">T50.A25A - T50.A25S</a>	Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter - Adverse effect of mixed bacterial vaccines without a pertussis component, sequela
<a href="#">T50.A95A - T50.A95S</a>	Adverse effect of other bacterial vaccines, initial encounter - Adverse effect of other bacterial vaccines, sequela
<a href="#">T50.B15A - T50.B15S</a>	Adverse effect of smallpox vaccines, initial encounter - Adverse effect of smallpox vaccines, sequela
<a href="#">T50.B95A - T50.B95S</a>	Adverse effect of other viral vaccines, initial encounter - Adverse effect of other viral vaccines, sequela
<a href="#">T50.Z15A - T50.Z15S</a>	Adverse effect of immunoglobulin, initial encounter - Adverse effect of immunoglobulin, sequela
<a href="#">T50.Z95A - T50.Z95S</a>	Adverse effect of other vaccines and biological substances, initial encounter - Adverse effect of other vaccines and biological substances, sequela
<a href="#">T50.905A - T50.905S</a>	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter - Adverse effect of unspecified drugs, medicaments and biological substances, sequela
<a href="#">T50.995A - T50.995S</a>	Adverse effect of other drugs, medicaments and biological substances, initial encounter - Adverse effect of other drugs, medicaments and biological substances, sequela
<a href="#">T63.011A - T63.044S</a>	Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter - Toxic effect of cobra venom, undetermined, sequela
<a href="#">T63.061A - T63.094S</a>	Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter - Toxic effect of venom of other snake, undetermined, sequela
<a href="#">T63.111A - T63.124S</a>	Toxic effect of venom of gila monster, accidental (unintentional), initial encounter - Toxic effect of venom of other venomous lizard, undetermined, sequela
<a href="#">T63.191A - T63.194S</a>	Toxic effect of venom of other reptiles, accidental (unintentional), initial encounter - Toxic effect of venom of other reptiles, undetermined, sequela
<a href="#">T63.2X1A - T63.2X4S</a>	Toxic effect of venom of scorpion, accidental (unintentional), initial encounter - Toxic effect of venom of scorpion, undetermined, sequela
<a href="#">T63.311A - T63.334S</a>	Toxic effect of venom of black widow spider, accidental (unintentional), initial encounter - Toxic effect of venom of brown recluse spider, undetermined, sequela
<a href="#">T63.391A - T63.394S</a>	Toxic effect of venom of other spider, accidental (unintentional), initial encounter - Toxic effect of venom of other spider, undetermined, sequela
<a href="#">T63.411A - T63.484S</a>	Toxic effect of venom of centipedes and venomous millipedes, accidental (unintentional), initial encounter - Toxic effect of venom of other arthropod, undetermined, sequela
<a href="#">T63.511A - T63.514S</a>	Toxic effect of contact with stingray, accidental (unintentional), initial encounter - Toxic effect of contact with stingray, undetermined, sequela
<a href="#">T63.591A - T63.594S</a>	Toxic effect of contact with other venomous fish, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous fish, undetermined, sequela
<a href="#">T63.611A - T63.634S</a>	Toxic effect of contact with Portugese Man-o-war, accidental (unintentional), initial encounter - Toxic effect of contact with sea anemone, undetermined, sequela

ICD-10 Codes	Description
<a href="#">T63.691A - T63.694S</a>	Toxic effect of contact with other venomous marine animals, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous marine animals, undetermined, sequela
<a href="#">T63.711A - T63.714S</a>	Toxic effect of contact with venomous marine plant, accidental (unintentional), initial encounter - Toxic effect of contact with venomous marine plant, undetermined, sequela
<a href="#">T63.791A - T63.794S</a>	Toxic effect of contact with other venomous plant, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous plant, undetermined, sequela
<a href="#">T63.811A - T63.834S</a>	Toxic effect of contact with venomous frog, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous amphibian, undetermined, sequela
<a href="#">T63.891A - T63.894S</a>	Toxic effect of contact with other venomous animals, accidental (unintentional), initial encounter - Toxic effect of contact with other venomous animals, undetermined, sequela
<a href="#">T78.00XA - T78.00XS</a>	Anaphylactic reaction due to unspecified food, initial encounter - Anaphylactic reaction due to unspecified food, sequela
<a href="#">T78.01XA - T78.09XS</a>	Anaphylactic reaction due to peanuts, initial encounter - Anaphylactic reaction due to other food products, sequela
<a href="#">T78.2XXA - T78.3XXS</a>	Anaphylactic shock, unspecified, initial encounter - Angioneurotic edema, sequela
<a href="#">T78.40XA - T78.40XS</a>	Allergy, unspecified, initial encounter - Allergy, unspecified, sequela
<a href="#">T78.49XA - T78.49XS</a>	Other allergy, initial encounter - Other allergy, sequela
<a href="#">T88.6XXA - T88.6XXS</a>	Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, initial encounter - Anaphylactic reaction due to adverse effect of correct drug or medicament properly administered, sequela
Z91.048	Other nonmedicinal substance allergy status
Z91.09	Other allergy status, other than to drugs and biological substances

ICD-10 Codes that DO NOT Support Medical Necessity N/A  
ICD-10 Additional Information

[Back to Top](#)

---

## General Information

### Associated Information

#### Documentation Requirements:

The patient's medical record must contain documentation that fully supports the medical necessity for services included within this LCD. (See "Indications and Limitations of Coverage.") This documentation includes, but is not limited to, relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures.

Each claim must be submitted with ICD-10-CM codes that reflect the condition of the patient, and indicate the reason(s) for which the service was performed. Claims submitted without ICD-10-CM codes will be returned.

Documentation must be available to Medicare upon request.

#### Utilization Guidelines:

It is expected that these services would be performed as indicated by current medical literature and/or standards of practice. When services are performed in excess of established parameters, they may be subject to review for medical necessity.

#### Sources of Information and Basis for Decision

This bibliography presents those sources that were obtained during the development of this policy. National Government Services is not responsible for the continuing viability of Web site addresses listed below.

Adkinson NF, Yunginger JW, Busse WW, et al Middleton's Allergy: Principles and Practice, 6th ed.

[Back to Top](#)

---

## Revision History Information

Please note: Most Revision History entries effective on or before 01/24/2013 display with a Revision History Number of "R1" at the bottom of this table. However, there may be LCDs where these entries will display as a separate and distinct row.

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2015	R3	The ICD-10 range T78.01XA-T78.49XS has been broken out to remove ICD-10 codes T78.1XXA-T78.1XXS and T78.41XA-T78.41XS.	<ul style="list-style-type: none"><li>• Revisions Due To ICD-10-CM Code Changes</li></ul>
10/01/2015	R2		<ul style="list-style-type: none"><li>• Revisions Due To ICD-10-CM Code Changes</li></ul>

Revision History Date	Revision History Number	Revision History Explanation	Reason(s) for Change
10/01/2015 R1		The following ICD-10 codes have been removed: T63.91XA - T63.94XA and T88.59XA. Add Bill type codes	• Other

---

## [Associated Documents](#)

Attachments N/A

Related Local Coverage Documents N/A

Related National Coverage Documents N/A

Public Version(s) Updated on 09/13/2015 with effective dates 10/01/2015 - N/A [Updated on 08/07/2015 with effective dates 10/01/2015 - N/A](#) [Updated on 07/13/2015 with effective dates 10/01/2015 - N/A](#) [Updated on 04/02/2014 with effective dates 10/01/2015 - N/A](#) [Back to Top](#)

---

## [Keywords](#)

N/A Read the [LCD Disclaimer](#) [Back to Top](#)